OPEN END TURBO LONG - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 20:47:51 24/06/2024 BST | ||
| 22.03 EUR | +1.94% |
|
| Current month | +9.77% | ||
| 1 month | +9.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24/06/24 | 22.03 | +1.94% |
| 21/06/24 | 21.61 | -0.14% |
| 20/06/24 | 21.64 | +2.51% |
| 19/06/24 | 21.11 | -0.71% |
| 18/06/24 | 21.26 | -3.06% |
Delayed Quote Börse Stuttgart
Last update June 24, 2024 at 08:47 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD5LCP |
| ISIN | DE000MD5LCP0 |
| Date issued | 27/06/2022 |
| Strike | 240.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 8.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.89 € |
|---|---|
| Lowest since issue | 6.89 € |
| Spread | 0.05 € |
| Spread % | 0.23% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475
USD
Average target price
464
USD
Spread / Average Target
-2.31%
- Stock Market
- Certificates
- Certificat
